Combining Pembrolizumab and Palliative Radiotherapy in Gastroesophageal Cancer to Enhance Anti-Tumor T Cell Response and Augment the Abscopal Effect
Phase of Trial: Phase II
Latest Information Update: 06 Apr 2017
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Squamous cell cancer
- Focus Biomarker; Pharmacodynamics
- 21 Jan 2017 Trial design presented at the 2017 Gastrointestinal Cancers Symposium
- 05 Oct 2016 Planned primary completion date changed from 1 Jul 2018 to 1 Oct 2018.
- 05 Oct 2016 Status changed from not yet recruiting to recruiting.